Medicortex Finland Oy logo

Medicortex Finland Oy

Medicortex Finland is dedicated to improving the diagnosis, treatment and prevention of acute neurodegenerative conditions and is currently focused on developing a novel multiplex treatment for traumatic brain injury.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.medicortex.fi
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Pharma CityItainen Pitkakatu 4 B, 4th floor,20520
Turku
Finland
Email
Contact Number
+358 400 488 817

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/medicortexfinlandoy” connections=”true” suffix=””]

The companys initial focus is on preventing secondary brain injury in TBI, a complex process caused by a multitude of biochemical changes. MediCortexs unique neuroprotective strategy is to introduce, multi-functional compounds that will address a number of biochemical & physiological pathways simultaneously.

May 2018, Medicortex entered into an agreement with Pro-Lab Diagnostics Inc for responsible for the regulatory process and registration of the ProbTBI_ brain injury detection kit in Canada and UK. The agreement gives Pro-Lab exclusive rights for sales in the UK and Canada from which Medicortex will receive royalties.

The company was awarded a Tekes grant by the government of Finland to develop new drugs to halt the process of neuronal degradation that persists following brain injury.